^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | garsorasib (D-1553) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Published date:
10/16/2023
Excerpt:
D-1553 is well tolerated and has shown promising anticancer activity in pts with pre-treated KRAS G12C mutated advanced PCa.
Trial ID:
Source:
Title:
932 - Discovery of D-1553, a novel and selective KRas-G12C Inhibitor with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Published date:
03/10/2021
Excerpt:
The anti-tumor activity of D-1553 is evaluated across a panel of cancer cell lines including lung, pancreatic and colorectal cancers and shown to be active only in cancer cells with KRas-G12C mutation....When D-1553 is combined with MEK inhibitor, SHP2 inhibitor or cytotoxic agents, further tumor growth inhibition or regression was observed in tumor xenograft models. These data suggest that D-1553 has anti-tumor activity in a broad spectrum of cancers and is suitable for tissue-agnostic clinical development targeting cancers with KRas-G12C mutation.
